The largest database of trusted experimental protocols

Tg mmtv cre 4mam j

Manufactured by Jackson ImmunoResearch
Sourced in United States

The Tg (MMTV-cre) 4Mam/J; is a transgenic mouse strain that expresses the Cre recombinase enzyme under the control of the mouse mammary tumor virus (MMTV) promoter. The Cre enzyme can be used for site-specific recombination in transgenic mouse models.

Automatically generated - may contain errors

6 protocols using tg mmtv cre 4mam j

1

Generating MMTV-Cre; mPot1aF/F; p53F/F Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
To generate MMTV-Cre; mPot1aF/F; p53F/F mice, MMTV-Cre mice (The Jackson Laboratory, Tg (MMTV-cre) 4Mam/J; stock number: 003553) were first crossed with mPot1aF/F mice (Wu et al., 2006 (link)) to generate MMTV-Cre; mPot1aF/F mice. MMTV-Cre; mPot1aF/F mice were then crossed with p53F/F (The Jackson Laboratory, B6.129P2-Trp53tm1Brn/J; Stock No:008462) mice to generate MMTV-Cre; mPot1aF/F; p53F/+ and MMTV-Cre; mPot1aF/F; p53F/F mice. mPot1aF/F and mPot1aF/F; p53F/F mice were generated as controls. All mice were maintained under basic care conditions according to the IACUC-approved protocols of Yale University. Sick mice (age 7–12 months old; Table S1) were sacrificed and tumors were harvested from breast glands or other organs. Chopped tumors were digested with 0.25% trypsin at 37° C for 15min followed by collagenase D treatment at 37° C for 30 min. The digested suspension was filtered through 40μm cell strainer and isolated tumor cells were pelleted by centrifugation and expanded by passaging in the DMEM with 10% FBS culture media.
+ Open protocol
+ Expand
2

Generating MMTV-Cre; mPot1aF/F; p53F/F Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
To generate MMTV-Cre; mPot1aF/F; p53F/F mice, MMTV-Cre mice (The Jackson Laboratory, Tg (MMTV-cre) 4Mam/J; stock number: 003553) were first crossed with mPot1aF/F mice (Wu et al., 2006 (link)) to generate MMTV-Cre; mPot1aF/F mice. MMTV-Cre; mPot1aF/F mice were then crossed with p53F/F (The Jackson Laboratory, B6.129P2-Trp53tm1Brn/J; Stock No:008462) mice to generate MMTV-Cre; mPot1aF/F; p53F/+ and MMTV-Cre; mPot1aF/F; p53F/F mice. mPot1aF/F and mPot1aF/F; p53F/F mice were generated as controls. All mice were maintained under basic care conditions according to the IACUC-approved protocols of Yale University. Sick mice (age 7–12 months old; Table S1) were sacrificed and tumors were harvested from breast glands or other organs. Chopped tumors were digested with 0.25% trypsin at 37° C for 15min followed by collagenase D treatment at 37° C for 30 min. The digested suspension was filtered through 40μm cell strainer and isolated tumor cells were pelleted by centrifugation and expanded by passaging in the DMEM with 10% FBS culture media.
+ Open protocol
+ Expand
3

Modeling MMTV-neu Breast Cancer

Check if the same lab product or an alternative is used in the 5 most similar protocols
MMTV-neu (FVB-Tg(MMTV-Erbb2)NK1Mul/J; RRID:IMSR_JAX:005038), MMTV-Cre (Tg(MMTV-cre)4Mam/J) and NSG mice (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ; RRID:IMSR_JAX:005557) were obtained from The Jackson Laboratory. CD36flox/flox mice were described previously (Nagendran et al., 2013 (link)). All animal studies were performed in accordance with protocols approved by the Institutional Animal Care and Use Committee (IACUC) at Dartmouth College and Kent State University. Female MMTV-neu mice were treated with 100 mg/kg lapatinib (LC Laboratories; Cat# 388082–77-7) or DMSO by oral gavage BID once a palpable tumor ~100mm3 was discovered (~1 year old). Tumor growth was monitored by caliper measurement every 3 days. Mice were sacrificed when reaching maximum tumor volume permitted by IACUC protocols. For xenograft studies, 1 × 107 BT474 or rBT474 cells resuspended in Matrigel Matrix (Corning; Cat# 354234) were implanted in the mammary fat pad of 6-week old female NSG mice. Upon reaching 300mm3, mice were randomly assigned to one of four treatment groups. Mice were treated with 100 mg/kg lapatinib or DMSO by oral gavage BID in combination with 10 μg anti-CD36 function blocking antibody (Clone JC63.1; Cayman Chemical; Cat# 188150; RRID:AB_10077812) or anti-mouse IgA-isotype control (Abcam; Cat# ab37322).
+ Open protocol
+ Expand
4

Conditional Genetic Manipulation in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
All mouse experiments were carried out at Baylor College of Medicine (BCM) and The Hospital for Sick Children with the approval of their respective Institutional Animal Care and Use Committees. All mice were housed in a pathogen-free facility. Mouse lines included: Gt(ROSA)26Sortm1Jus – ‘R26PR’ (Carofino et al., 2013 (link)), Gt(ROSA)26Sortm2Jus – ‘R26FLPR’ (both generated by Justice Laboratory), Tg(MMTV-cre)4Mam/J – ‘MMTV-cre’ (The Jackson Laboratory, Bar Harbor, Maine, US), Tg(Mx1-cre)1Cgn/J – ‘Mx1-cre’ (from Dr Margaret A. Goodell, Baylor College of Medicine, Houston, Texas, US), and Rag1tm1Mom/J – ‘Rag1−/−’ (from Dr David Corry, Baylor College of Medicine, Houston, Texas, US). All lines were on a C57BL/6 (J or N) background, with the exception of MMTV-cre (B6.129 F1 hybrid). The R26FLPR line was generated as previously described (Carofino et al., 2013 (link)), except for the addition of an N-terminal FLAG tag and the addition of P2A-eGFP rather than IRES-eGFP. P2A-eGFP was amplified from OCT4-2A-eGFP-PGK-Puro, which was a gift from Rudolf Jaenisch (Addgene plasmid # 31938). Mx1-cre was activated in both the R26PR;Mx1-cre and R26FLPR;Mx1-cre lines via intraperitoneal injection of 250 µg polyinosinic:polycytidylic acid (pIpC) (Sigma-Aldrich), with three doses spaced two days apart and one dose, respectively, at 8 weeks of age.
+ Open protocol
+ Expand
5

Modeling MMTV-neu Breast Cancer

Check if the same lab product or an alternative is used in the 5 most similar protocols
MMTV-neu (FVB-Tg(MMTV-Erbb2)NK1Mul/J; RRID:IMSR_JAX:005038), MMTV-Cre (Tg(MMTV-cre)4Mam/J) and NSG mice (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ; RRID:IMSR_JAX:005557) were obtained from The Jackson Laboratory. CD36flox/flox mice were described previously (Nagendran et al., 2013 (link)). All animal studies were performed in accordance with protocols approved by the Institutional Animal Care and Use Committee (IACUC) at Dartmouth College and Kent State University. Female MMTV-neu mice were treated with 100 mg/kg lapatinib (LC Laboratories; Cat# 388082–77-7) or DMSO by oral gavage BID once a palpable tumor ~100mm3 was discovered (~1 year old). Tumor growth was monitored by caliper measurement every 3 days. Mice were sacrificed when reaching maximum tumor volume permitted by IACUC protocols. For xenograft studies, 1 × 107 BT474 or rBT474 cells resuspended in Matrigel Matrix (Corning; Cat# 354234) were implanted in the mammary fat pad of 6-week old female NSG mice. Upon reaching 300mm3, mice were randomly assigned to one of four treatment groups. Mice were treated with 100 mg/kg lapatinib or DMSO by oral gavage BID in combination with 10 μg anti-CD36 function blocking antibody (Clone JC63.1; Cayman Chemical; Cat# 188150; RRID:AB_10077812) or anti-mouse IgA-isotype control (Abcam; Cat# ab37322).
+ Open protocol
+ Expand
6

Inducible Cre-driven CRTC1-MAML2 Fusion Transgenic Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
The Cre-regulated CRTC1-MAML2 transgenic mice were crossed with homozygous transgenic MMTV-Cre mice (Tg[MMTV-cre]4Mam/J, 003553, The Jackson Laboratory) to induce expression of the CRTC1-MAML2 fusion transgene in salivary gland. Mice carrying the fusion transgene were identified by PCR as described above. Nontransgenic littermates were used as negative controls.
The Cre-regulated CRTC1-MAML2 transgenic mice were also crossed with the Dcpp1tm1.1 (cre/ERT2)Ovi (028731, Jackson Laboratory; designated as “dCre-ERT2”), and Piptm1.1(cre/ERT2)Ovi (023201, Jackson Laboratory; designated as “pCre-ERT2”). dCre-ERT2 is a tamoxifen–inducible (TAM-inducible) Cre strain in which a fusion of Cre to a mutant form of human estrogen receptor (ERT2) was inserted right after the initiation ATG codon of Dcpp1 exon 1, and its TAM-induced Cre expression was specific to sublingual serous demilune cells and intercalated duct cells in parotid glands (38 (link)). pCre-ERT2 is a TAM-inducible Cre strain in which exon 1 of Pip gene is replaced by Cre-ERT2 fusion, and its TAM-induced Cre expression was specific to acinar cells in submandibular glands (38 (link)). TAM (75 mg/kg body weight) was i.p. injected to mice at about 4 weeks of age once daily for 3 consecutive days.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!